Furthermore, in a phase III KEYNOTE-024 study (NCT02142738) pembrolizumab treatment in NSCLC patients with PD-L1 tumor proportion score of 50% or higher demonstrated higher progression-free survival compared to those treated with platinum-based chemotherapy [98]. Here, CD274 is linked to non-small cell lung carcinoma.